DAHANCA 25A: Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01025518 |
Recruitment Status :
Completed
First Posted : December 3, 2009
Last Update Posted : November 29, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Head and Neck Neoplasms | Other: Resistance training Dietary Supplement: Protein and creatine Dietary Supplement: Placebo | Not Applicable |
Head and neck cancer patients experience a significant loss of muscle mass following radiotherapy treatment due to cachexia and dysphagia. This negatively affects muscle strength and functional capacity.
Studies on healthy individuals and various groups of patients show that resistance training in combination with protein and creatine ingestion is an effective means of increasing muscle mass, strength and functional capacity.
Thus the aim is to investigate the following:
- is resistance training and dietary supplements tolerable among head and neck cancer patients
- the effect of the intervention on muscle mass, strength and functional capacity
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Supportive Care |
Official Title: | A Randomized Trial Evaluating Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients |
Study Start Date : | September 2009 |
Actual Primary Completion Date : | January 2012 |
Actual Study Completion Date : | January 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: resistance training and dietary supplement |
Other: Resistance training
12 weeks of resistance training in combination with protein and creatine or placebo ingestion Dietary Supplement: Protein and creatine 30 g of protein with each training session, 5 g of creatine pr day
Other Name: In2Zyme WP80 and In2Zyme Biodrive 1 |
Placebo Comparator: Resistance training and placebo ingestion
12 weeks of resistance training and placebo ingestion
|
Other: Resistance training
12 weeks of resistance training in combination with protein and creatine or placebo ingestion Dietary Supplement: Placebo Maltodextrine |
- Muscle mass and muscle strength [ Time Frame: 13 weeks ]
- Functional capacity [ Time Frame: 13 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- head and neck cancer patients (localized to the larynx, pharynx and oral cavity) treated with curative radiotherapy
- complete loss of tumor
- WHO performance status between 0-1 and expected ability to complete the training protocol
- No parenteral feeding
- above the age of 18
- written concent
Exclusion Criteria:
- other malignant diseases
- pregnancy
- undergoing systematic resistance training or creatin ingestion
- Alcohol abuse

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01025518
Denmark | |
Dept. of Experimental Clinical Oncology, Aarhus University Hospital | |
Aarhus, Region Midt, Denmark, 8000 | |
Dept. of Experimental Clinical Oncology | |
Aarhus, Denmark, 8000 |
Study Chair: | Jens Overgaard, Professor, MD | DAHANCA |
Responsible Party: | Jens Overgaard, Professor, MD, Danish Head and Neck Cancer Group |
ClinicalTrials.gov Identifier: | NCT01025518 |
Other Study ID Numbers: |
DAHANCA 25A CIRRO-IP010309 ( Other Grant/Funding Number: CIRRO ) Ethical Comittee: 20090181 |
First Posted: | December 3, 2009 Key Record Dates |
Last Update Posted: | November 29, 2016 |
Last Verified: | November 2016 |
Head and Neck Neoplasms Resistance training Muscle mass Functional capacity |
Head and Neck Neoplasms Neoplasms Neoplasms by Site |